3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
3
Recurrence
1
Metastatic Castration-Resistant Prostate Cancer
1
Adenocarcinoma
1
Interventions
Peripheral Blood Stem Cell Transplantation
6
Cyclophosphamide
6
fludarabine phosphate
5
Nivolumab
5
Mycophenolic Acid
5
Carboplatin
5
Whole-Body Irradiation
4
Radiotherapy
4
Filgrastim
4
Cyclosporine
4
Gemcitabine
3
Cisplatin
3
Busulfan
3
Antilymphocyte Serum
3
cabozantinib
2
cabazitaxel
2
Voriconazole
2
Thiotepa
2
Therapeutics
2
Standard of Care
2
Sirolimus
2
Polymerase Chain Reaction
2
Mitomycin
2
Methylprednisolone
2
Methotrexate
2
Melphalan
2
Itraconazole
2
Immunoglobulin G
2
Goserelin
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
PF06821497
×
Genitourinary
×
Clear all
NCT06551324
2026-05-05
MEVPRO-1
Pfizer
Phase 3
Active not recruiting
600 enrolled